438 related articles for article (PubMed ID: 15380054)
21. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
22. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
Agha AH; Roy JB; Culkin DJ; Lyon K
Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332
[TBL] [Abstract][Full Text] [Related]
23. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial.
Kaplan SA; Roehrborn CG; McConnell JD; Meehan AG; Surynawanshi S; Lee JY; Rotonda J; Kusek JW; Nyberg LM;
J Urol; 2008 Sep; 180(3):1030-2; discussion 1032-3. PubMed ID: 18639298
[TBL] [Abstract][Full Text] [Related]
24. [Using doxasosine and finasteride combination in the treatment of prostate adenoma].
Bogdanov AB; Luk'ianov IV; Veliev EI
Urologiia; 2006; (5):59-63. PubMed ID: 17444154
[TBL] [Abstract][Full Text] [Related]
25. Finasteride in benign prostatic hyperplasia.
Verhamme KM; Bosch RJ; Sturkenboom MC
N Engl J Med; 2004 Mar; 350(13):1359-61; author reply 1359-61. PubMed ID: 15049034
[No Abstract] [Full Text] [Related]
26. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.
Fitzpatrick JM; Desgrandchamps F
BJU Int; 2005 Mar; 95(4):575-9. PubMed ID: 15705083
[TBL] [Abstract][Full Text] [Related]
27. A cost comparison of medical management and transurethral needle ablation for treatment of benign prostatic hyperplasia during a 5-year period.
Naslund MJ; Carlson AM; Williams MJ
J Urol; 2005 Jun; 173(6):2090-3; discussion 2093. PubMed ID: 15879849
[TBL] [Abstract][Full Text] [Related]
28. Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia.
Fwu CW; Eggers PW; Kaplan SA; Kirkali Z; Lee JY; Kusek JW
J Urol; 2013 Jul; 190(1):187-93. PubMed ID: 23357210
[TBL] [Abstract][Full Text] [Related]
29. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
[TBL] [Abstract][Full Text] [Related]
30. Benign prostatic hyperplasia (BPH).
Harv Mens Health Watch; 2006 Aug; 11(1):3. PubMed ID: 17111474
[No Abstract] [Full Text] [Related]
31. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia.
Johnson TM; Burrows PK; Kusek JW; Nyberg LM; Tenover JL; Lepor H; Roehrborn CG;
J Urol; 2007 Nov; 178(5):2045-50; discussion 2050-1. PubMed ID: 17869295
[TBL] [Abstract][Full Text] [Related]
32. [Comparative evaluation of the effectiveness and safety of combined drug therapy of patients with benign prostatic hyperplasia with finasteride and alfuzozine].
Loran OB; Pushkar' DIu; Rasner PI
Urologiia; 2002; (1):19-22. PubMed ID: 11877966
[TBL] [Abstract][Full Text] [Related]
33. A comparative study of: long-term alpha-1-blocker, Doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia.
Dutkiewicz S
Mater Med Pol; 1995; 27(4):151-2. PubMed ID: 9000839
[TBL] [Abstract][Full Text] [Related]
34. Under what conditions is feedback microwave thermotherapy (ProstaLund Feedback Treatment) cost-effective in comparison with alpha-blockade in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms?
Ragnarson Tennvall G; Hjelmgren J; Malmberg L
Scand J Urol Nephrol; 2006; 40(6):495-505. PubMed ID: 17130102
[TBL] [Abstract][Full Text] [Related]
35. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
Roehrborn CG; Bruskewitz R; Nickel JC; McConnell JD; Saltzman B; Gittelman MC; Malek GH; Gottesman JE; Suryawanshi S; Drisko J; Meehan A; Waldstreicher J;
J Urol; 2004 Mar; 171(3):1194-8. PubMed ID: 14767299
[TBL] [Abstract][Full Text] [Related]
36. The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms: at 2 years of followup, does it work?
Kaplan SA; Olsson CA; Te AE
J Urol; 1996 Jun; 155(6):1971-4. PubMed ID: 8618299
[TBL] [Abstract][Full Text] [Related]
37. [5-alpha reductase inhibitors or alpha blockers? The combination brakes best prostatic hyperplasia].
MMW Fortschr Med; 2002 Oct; 144(44):56. PubMed ID: 12494605
[No Abstract] [Full Text] [Related]
38. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
[TBL] [Abstract][Full Text] [Related]
39. [Benign prostatic hyperplasia: medical therapy].
Schlenker B; Gratzke C; Weidlich P; Seitz M; Reich O; Stief CG
MMW Fortschr Med; 2007 Aug; 149(33-34):29-31; quiz 32. PubMed ID: 17912863
[TBL] [Abstract][Full Text] [Related]
40. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy.
Fwu CW; Eggers PW; Kirkali Z; McVary KT; Burrows PK; Kusek JW
J Urol; 2014 Jun; 191(6):1828-34. PubMed ID: 24342143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]